Effects of aluminum-salt, CpG and emulsion adjuvants on the stability and immunogenicity of a virus-like particle displaying the SARS-CoV-2 receptor-binding domain (RBD)Research Article Published on 2023-11-062024-09-05 Journal: Human vaccines & immunotherapeutics [Category] update2024, [키워드] adjuvant aluminum-salt Antigen CpG Emulsion Formulation SARS-CoV-2 stability Vaccine VLP (virus-like particle) [DOI] 10.1080/21645515.2023.2264594 PMC 바로가기 [Article Type] Research Article
SARS-CoV-2 within-host diversity of human hosts and its implications for viral immune evasionarticle Published on 2023-06-052024-09-05 Journal: mBio [Category] update2024, [키워드] CpG immune evasion iSNVs RNA editing SARS-CoV-2 within-host diversity ZAP [DOI] 10.1128/mbio.00679-23 PMC 바로가기 [Article Type] article
Immunoadjuvant efficacy of CpG plasmids for H9N2 avian influenza inactivated vaccine in chickens with maternal antibodiesArticle Published on 2023-05-012023-06-22 Journal: Veterinary Immunology and Immunopathology [Category] 조류인플루엔자, [키워드] CpG H9N2 avian influenza Maternal-derived antibodies (MDAs) Passively transferred antibodies (PTAs) vaccine adjuvant [DOI] 10.1016/j.vetimm.2023.110590
A trimeric spike-based COVID-19 vaccine candidate induces broad neutralization against SARS-CoV-2 variantsCoronavirus Published on 2023-03-072024-09-05 Journal: Human vaccines & immunotherapeutics [Category] update2024, [키워드] aluminum hydroxide adjuvant CpG cross-neutralization S-Trimer protein SARS-CoV-2 Vaccine [DOI] 10.1080/21645515.2023.2186110 PMC 바로가기 [Article Type] Coronavirus
Sex-biased expression of the TLR7 gene in severe COVID-19 patients: Insights from transcriptomics and epigenomicsArticle Published on 2022-12-012022-11-16 Journal: Environmental research [Category] 유전자 메커니즘, [키워드] acute phase analyzed Blood Cohort coronavirus disease COVID-19 COVID-19 patient CpG DNA DNA methylation dose downregulated embryogenesis epidemiological data epigenomic epigenomics Evidence expression female females gene product Genetic variation Genome-wide association studies Host inactivation incidence incidence of COVID-19 independent insight long-COVID-19 male males Methylation n-Counter. nasal patients Post-infection RNAseq Saliva Severe case severe COVID-19 severity Sex significantly higher stratified suggested timepoint TLR7 TLR7 gene transcriptomics with COVID-19 [DOI] 10.1016/j.envres.2022.114288 PMC 바로가기
Antigen-adjuvant interactions, stability, and immunogenicity profiles of a SARS-CoV-2 receptor-binding domain (RBD) antigen formulated with aluminum salt and CpG adjuvantsArticle Published on 2022-11-302022-11-15 Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 진단, [키워드] abrogated ACE2 addition adjuvant adjuvants Adsorption alum aluminum Analysis Antigen approach binding booster Combination Complete conformational Coverage COVID-19 COVID-19 vaccine CpG decrease demonstrated destabilized domain dose ELISA exacerbated facilitate Formulation highlight host cell receptor immune responses immunogenicity IMPROVE in vitro in vivo Interaction interactions mice neutralize neutralizing antibody profile Protein RBD RBD antigen SARS-CoV-2 SARS-CoV-2 pseudovirus spike stability stability profile subunit vaccines temperature the receptor-binding domain Vaccine while [DOI] 10.1080/21645515.2022.2079346 PMC 바로가기
Universal and Translational Nanoparticulate CpG AdjuvantArticle Published on 2022-11-162023-06-24 Journal: ACS applied materials & interfaces [Category] 신종인플루엔자, [키워드] CpG Flash nanocomplexation nanoadjuvant translational potential universal performance. [DOI] 10.1021/acsami.2c15644
Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulation as a Second Generation Covid-19 VaccineArticle Published on 2022-10-252022-11-15 Journal: ACS Nano [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, [키워드] ACM acute respiratory syndrome adverse effect airway antibodies antibody antigen presenting cells artificial Beta Beta spike C57BL/6 cell membrane clinical symptom clinical trial component conditions coronavirus coronavirus disease COVID-19 CpG cross-neutralizing current delivery of cargo dendritic cells dose doses evaluate evaluated Formulation generate Generation Good hamster hamsters immune responses immunization immunogenic induce Infection initiated interval intranasal mice neutralize neutralizing antibody neutralizing responses New omicron Phase 1 polymersome Practice PROTECT reduction repeated Safety SARS-CoV-2 second serum IgG spike Spike protein Spike-based vaccine Support Toxicity upper respiratory tract Vaccine variants viral clearance Viral load virus weight loss wild type [DOI] 10.1021/acsnano.2c06350 PMC 바로가기
Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathologyArticle Published on 2022-09-292022-11-15 Journal: Vaccine [Category] SARS, 변종, 진단, [키워드] acute respiratory syndrome Adaptive immune response addition antibodies antibody Beta Cell coronavirus coronavirus disease COVID-19 COVID-19 vaccines CpG cross-protective develop feature Gamma IgA antibody IgG antibody immunopathology Infection initial intranasal intranasal vaccination intranasally investigated less lung Lung eosinophilic immunopathology Lymph node mice mucosa nasal nasal mucosa oligonucleotides pandemic potential risk Prevent Protective protective effect reducing Respiratory disease risk SARS-CoV-2 SARS-CoV-2 variant secretory secretory IgA secretory IgA antibody. serum spike-specific IgG subcutaneous vaccination subcutaneously T helper Th1 Th2 Trimeric spike protein upper respiratory tract vaccination Vaccine variant variants viral challenge virus infection viruses [DOI] 10.1016/j.vaccine.2022.08.049 PMC 바로가기
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults비활성화된 전체 바이러스 면역증강제 COVID-19 백신 VLA2001의 안전성 및 면역원성: 건강한 성인을 대상으로 한 무작위, 용량 증량, 이중 맹검 1/2상 임상 시험Clinical Trial Published on 2022-09-012022-09-12 Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Adjuvanted vaccine binding clinical development clinical trial conducted convalescent sera coronavirus COVID-19 COVID-19 vaccine CpG CpG 1018 dose Dose escalation dose-escalation double-blind evaluate expressing Frequency geometric mean titre GMT groups headache healthy High dose high-dose group highest dose IFN-γ IgG immunogenicity inactivated Inactivated vaccine injection Local medium N protein neutralizing antibody Open-label optimal dose outcome participant Phase 3 primary immunogenicity priming Randomized randomized trial RBD-binding IgG RBD-binding IgG antibody reactive recruited Registered reported S protein S protein binding IgG antibody Safety SARS-CoV-2 SARS-CoV-2 neutralizing antibody second vaccination severity significantly significantly higher statistically systemic reaction T-cell tested titre Tolerability vaccination Vaccine VLA2001 was selected Whole-virus vaccine. [DOI] 10.1016/j.jinf.2022.06.009 PMC 바로가기 [Article Type] Clinical Trial